Home | Medical-Newswire.Com:
(Medical-NewsWire.com, September 20, 2012 ) New York, NY -- Advanced Medical Isotope Corporation (ADMD) is already a US-based manufacturer and distributor of medical isotopes and is also developing key technologies that may offer a superior alternative to the current standard of care for battling cancer with nuclear medicine.
In a Thursday report, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies key point for optimism regarding the company and examines its speculative potential as an investment. Full report available at: http://vfcsstockhouse.com/blog/article/-advanced-medical-isotope-corporation-expanded-distribution-and-radiogel-technology-hold-the-keys-to-the-future
Advanced Medical Isotope Corporation (ADMD) has - through key partnerships, expanding distribution channels and the acquisition of a license to a novel cancer-fighting technology - well positioned itself to become a growth player in the field of nuclear medicine, specifically in the field of the production and distribution of medical isotopes. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases and are deemed a hot item whenever discussed because of the geopolitical implications of non-nuclear nations attempt to enrich uranium for - ahem - solely medical purposes.
Advanced Medical is one of only a few companies in the United States manufacturing and distributing such isotopes and it's likely that business could quickly hit a growth spurt - not only through the company's own indigenous expansion and distribution efforts, but also because of the growing desire of the medical community in the US to use 'home grown' nuclear materials, not to mention increasing regulation that may force the community to do so anyway.
AMIC already offers a broad variety of isotopes and, as outlined in a recent quarterly report, is looking to expand its 'pipeline' of product offerings for its distribution network of customers that include - but is not limited to - national laboratories, hospitals, research facilities and universities.
Many of the company's isotopes are put to use through molecular imaging, or Positron Emission Tomography (PET), which enables Doctors and medical professionals to identify cancerous condictions well before detection means that search for tumor mass. Some of the radiopharmaceutical products based on the medical isotopes are also used in the early detection of certain cardiovascular indications and, as mentioned above, the demand for such products is growing, not shrinking. According to numbers identified in a recent company presentation and credited to the World Nuclear Association, the use of medical isotopes is growing at an annual rate of 10%.
That places AMIC right in the middle of a potential growth boom.
While production and distribution may encompass the company's core business model, AMIC is moving heavily into the field of treatment, too. The process of placing radioactive "seeds" in or near a cancerous tumor is known as brachytherapy, and AMIC is developing a pipeline based on such technology to augment the already-growing core business plan.
In April, the company acquired a license and numerous relating patents to an injectible radiogel technology that could have a significant impact on the next generation of fighting cancer. Using the radiogel technology doctors could deliver Yttrium-90 "microspheres" directly into cancerous tissue. Because the injectible polymer turns solid and holds the microspheres in place, there is little to no threat of any radiation escaping and damaging surrounding tissue. As described by Dr. Alan Walter, Chair of the AMIC Scientific Committee, in a presentation available on the company's home page, such a technology could be termed as using "smart bullets" to target cancerous cells.
Yttrium-90, in the form of Polymer seeds, is an already-established medical isotope with numerous applications in existing cancer treatment and has demonstrated effectiveness in combating head, neck, liver and prostate cancers, according to an above-linked company presentation. The radiogel application of Yttrium-90 could potentially 'storm the scene' in treating numerous cancer types with the intent of targeting those tumors in the hard-to-get to areas of the body that eliminates surgery as an option.
Both the Polymer seeds and the acquired the radiogel technology significantly boost the diversity of AMIC, offering a targeted path to enter the realm of caner treatment to augment the production, sales and distribution channels of its isotopes.
It's possible, based on previous expectations, that the Brachytherapy pipeline could hit market within a couple of years. At that point AMIC could either move forward with commercialization on its own or out-license the technology to someone else and use that revenue stream of royalties to fund the expansion of the core business.
Shares were up by eight percent on Wednesday, although volume was very light. That said, volume has been picking up significantly over the past few months and has tripled already once this year. Volume has also stormed in after the company's more relevant press releases, indicating that there are investors on the sidelines who either wait to play a quick trade or may be taking a 'wait and see' approach to playing this still-speculative stock.
Should the potential of the AMIC distribution network continue to expand and meet the growing demand for nuclear medicine - and should the polymer seeds and radiogel technology also hit market with momentum - then it's likely that the current ADMD share price could start to move. Currently, shares consistently trade for a few pennies above the twenty cents mark, give or take.
Based on the potential of the developing technology, already-available products and future product offerings, the current ADMD trading levels could serve as an opportune accumulation period to those looking at the risk/reward profile for the future. The current market cap of still under twenty million indicates that many investors are still unconvinced, but when searching for potential payoff picks on the bulletin board stocks, it pays off to be in while the stock is still moving along relatively unnoticed, as the best percentage gains to be had in any run start with being in place before the run starts.
That said, the stock market is risky business and there are no sure things, that's why it's up to each investor to conduct his or her own DD and invest accordingly.
Still a developing story worth monitoring.
Disclosure: No position.
Follow ADMD developments and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: email@example.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights and opinions into broader-market news. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and make informed and well thought-out investment decisions. For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Health care site flagged in Heartbleed review
18 Apr 2014 at 10:18pm
WASHINGTON (AP) ? People who have accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the confounding Heartbleed Internet security flaw.
Study: Half of jailed NYC youths have brain injury
18 Apr 2014 at 2:35pm
NEW YORK (AP) ? About half of all 16- to 18-year-olds coming into New York City's jails say they had a traumatic brain injury before being incarcerated, most caused by assaults, according to a new study that's the latest in a growing body of research documenting head trauma among young offenders.
Second wave of milder flu hitting Northeast
18 Apr 2014 at 2:25pm
NEW YORK (AP) ? A second, milder wave of flu is hitting the Northeast.
Gunmen kidnap two Pakistani U.N. staff members from Karachi
19 Apr 2014 at 1:08am
By Syed Raza Hassan ISLAMABAD (Reuters) - Gunmen have kidnapped two men working for the U.N. Children's Fund from Pakistan's southern city of Karachi, police said Saturday. A spokeswoman for the U.N. Children's Fund, also known as UNICEF, was not available to comment. The port city of Karachi is Pakistan's financial heart and home to 18 million people. Many neighborhoods are considered Taliban strongholds, including the area of Shorab Goth, which is near where the men were taken.
APNewsBreak: Medicaid paid $12M for Illinois dead
18 Apr 2014 at 4:42pm
CHICAGO (AP) ? The Illinois Medicaid program paid an estimated $12 million for medical services for people listed as deceased in other state records, according to an internal state government memo.
Watch: Scientists Engineer Lab-Grown Vaginas
18 Apr 2014 at 3:03pm
Four women with a genetic condition took part in a ground-breaking study.
Yoga may help women ease PTSD symptoms
18 Apr 2014 at 2:36pm
By Shereen Jegtvig NEW YORK (Reuters Health) - Women enrolled in a small study reported a reduction in symptoms of posttraumatic stress disorder (PTSD) after a series of yoga classes. However, women in a comparison group that didn't take the classes also reported a similar decline in symptoms, researchers found. "The yoga group did well - they improved in their PTSD symptoms - and our control group actually did well, which we didn't expect," Karen Mitchell told Reuters Health. Mitchell, from the National Center for PTSD at the VA Boston Healthcare System, led the new study.
Supreme Court denies Teva stay in Copaxone patent fight
18 Apr 2014 at 1:49pm
By Lawrence Hurley WASHINGTON (Reuters) - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug. The decision could help pave the way for generic competitors of Teva's Copaxone drug to go on the market as soon as next month. Teva had sought to prevent the lower-court ruling from going into effect while the Supreme Court considers its appeal in the patent fight. At issue is a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one comprising Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc, and the other comprising Mylan Inc and Natco Pharma Ltd. In his decision on Friday, Roberts, in a brief opinion, wrote that he was not convinced Teva had shown the "likelihood of irreparable harm" if the application was denied, because if Teva wins the Supreme Court case it can seek damages from the generic companies for past infringement on its patents.
AbbVie urges U.S. court to avoid gay rights issue in HIV drug case
18 Apr 2014 at 12:57pm
An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians. In a brief filed with the 9th U.S. Circuit Court of Appeals in San Francisco on Thursday, AbbVie Inc said the full court should review an initial three-judge decision that found a gay man was improperly excluded from jury service due to his sexual orientation. The court in reaching that conclusion in January ordered a new trial for GlaxoSmithKline Plc against AbbVie, which contended Thursday that the 9th Circuit's ruling needed review due to its potential to affect "thousands of jury trials." But AbbVie said it is not asking for the court to reconsider a holding that heightened the constitutional protections judges in several Western states must now apply when evaluating laws that curtail gay rights.
Top Hollande aide quits in conflict of interest row
18 Apr 2014 at 12:43pm
By Julien Ponthus and Nicholas Vinocur CLERMONT-FERRAND, France (Reuters) - A senior adviser to French President Francois Hollande quit on Friday over accusations of past conflict of interest linked to his work for pharmaceutical firms, adding to pressure on the unpopular Socialist leader weeks before European elections. Aquilino Morelle, Hollande's chief communications adviser, speechwriter and a main political strategist, has denied investigative website Mediapart's report that he had failed to obtain clearance for lobbying work when he was an employee of the public health inspectorate. The furore deals another blow to Hollande after heavy losses for his party in town hall elections at the end of March. Hollande, speaking during a visit to Clermont Ferrand in central France, said his aide had "taken the only option open to him".
Clock ticking for states to adopt health exchanges
18 Apr 2014 at 12:12pm
CHICAGO (AP) ? For the more than 30 states that defaulted to the federal government under President Barack Obama's health care law, time may be running out to decide whether to create their own state-run insurance exchanges.
Watch: Baby Can't Open Mouth in Medical Mystery
18 Apr 2014 at 12:09pm
Video shows doctors assessing Wyatt Scott's ability to swallow.
Baby Can?t Open Mouth in Medical Mystery
18 Apr 2014 at 12:08pm
The Scott family started a website to find out what's wrong with baby Wyatt.
Exclusive: Biogen prices hemophilia drug on par with older therapies
18 Apr 2014 at 12:04pm
Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide. "We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis," Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview.
Lack of insurance tied to more emergency surgery: study
18 Apr 2014 at 12:01pm
By Andrew M. Seaman NEW YORK (Reuters Health) - The type of insurance people have is tied to their risk of needing emergency aorta surgery, according to a new study. Compared to people with private insurance, people without insurance were more likely to need emergency surgery on their aorta, the largest artery that supplies blood to every part of the body. Hughes is the study's senior author from Duke University Medical Center in Durham, North Carolina.